Jenica Upshaw is a Cardiology physician affiliated with Deaconess Hospital. OpenAlex indexes 118 publications with 1,225 citations (h-index 19); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
800 Washington St
Boston, MA 021111552
Telephone
617-363-5000Registry record last updated 7 Jan 2016.
Clinical trials
- The CARDIOPROTECT Trial
Sponsor: Beth Israel Deaconess Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
74.3%Statin18.3%Atorvastatin Calcium50%Rosuvastatin Calcium50%Part D≥20 patientsBeta blocker14.5%Metoprolol Succinate81%Carvedilol20%Part D<11 patients+ 8 more classes in this area
Metabolism & gastrointestinal
22.6%SGLT2 inhibitor15.9%Farxiga87%Jardiance13%Part D<11 patientsProton pump inhibitor4.4%Esomeprazole Magnesium52%Pantoprazole Sodium48%Part D<11 patients+ 1 more class in this area
Blood & clotting
3.2%Factor Xa inhibitor3.2%Eliquis100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2020–2025 per NIH RePORTER. The latest:
- A randomized trial of cardioprotective strategies in newly diagnosed diffuse large B-cell lymphoma and pre-existing cardiomyopathy or prior anthracycline exposure
Beth Israel Deaconess Medical Center
FY2025$818,625R37CA300969 - Prevention of Anthracycline Chemotherapy Cardiotoxicity
Beth Israel Deaconess Medical Center
FY2024$128,976K08HL146959
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”